Expansion of Bi-Partisan 39-State Attorney General Investigation of Opioid Manufacturers and Distributors

1238683_untitledBy press release on September 19, 2017, Massachusetts Attorney General Maura Healey announced the expansion of a pending review of an opioid related scheme to include additional manufacturers and distributors of opioids.  The investigation has been undertaken by a 39-member bipartisan group of state attorneys general, which was first announced earlier this past summer.  Our business and health care law firm follows developments in the pharmaceutical industry and our Country’s opioid addiction and overdose crisis that has led to many thousands of deaths and, in particular, related issues in Georgia and South Carolina.

According to the press release, the following companies are under investigation: Teva, Allergan, Endo, Janssen, Purdue Pharma.  The review and investigation concerns questions raised by the marketing and sale of opioids.  Initially, the investigation focused on manufacturer Purdue Pharma, then extended to other manufacturers and distributors. The following distributors are under investigation: McKesson, Cardinal Health and AmerisourceBergen.  Among other things, the attorneys general are seeking to obtain and review documents and information about sales and distribution practices of the subject manufacturers and distributors.

The Underlying National Crisis

Prescription opioid pain relievers have presented the United States with an unprecedented crisis.  According to the National Institute on Drug Abuse (NIDA), the problem began in the late 1990s by assurances from pharmaceutical manufacturers that prescription opioid pain relievers would not create an addiction problem.  Physicians, medical practices, hospitals and other providers thereafter began to prescribe them more.  Diversion and misuse followed and overdose rates increased.  For example, by 2015, about 2 million Americans suffered from substance use disorders attributable to opioids, according to the NIDA.  The NIDA has concluded as follows about the opioid crisis:

  • As much as one fourth of all patients prescribed opioids for pain management misuse them and between 8 and 12 percent develop an “opioid disorder.”
  • About 5 % of those patients who misuse opioid will transition to heroin.
  • Of all the people who use heroin, about 80% first misused opioids.

The Centers for Disease Control and Prevention (CDC) estimates that about 20% of all patients presenting to medical practices with noncancer pain symptoms or pain-related diagnoses receive an opioid prescription.  In 2012, health care providers wrote 259 million prescriptions for opioid pain medication, enough for every adult in the United States to have a bottle of pills. Opioid prescriptions per capita increased 7.3% from 2007 to 2012, with opioid prescribing rates increasing more for family practice, general practice, and internal medicine compared with other specialties. Rates of opioid prescribing vary greatly across states in ways that cannot be explained by the underlying health status of the population, highlighting the lack of consensus among clinicians on how to use opioid pain medication.

The most common prescription opioids are: hydrocodone (e.g., Vicodin), oxycodone (e.g., OxyContin, Percocet), oxymorphone (e.g., Opana), morphine (e.g., Kadian, Avinza), codeine and fentanyl.  Opioids work on the brain and are used to inhibit the transmission of pain signals in the body.  Side effects, including drowsiness, mental confusion, nausea, constipation, and depression are very common. The CDC has developed important guidelines for prescribing opioids in primary care settings.

Opioid Law Enforcement Activities

Healey and other state attorneys general have undertaken a massive collective effort to investigate and prosecute civil and criminal law enforcement actions to combat the opioid crisis, including actions in partnership with the Federal government.  The investigation summarized above is one of many that are part of a broad net cast by State and Federal law enforcement for offending manufacturers, distributors, and healthcare providers.


If you have questions about this post, you may contact our business and healthcare law firm at info@hamillittle.com or either of our two Georgia offices.


** Disclaimer: Thoughts shared here do not constitute legal advice. Please consult with an attorney to discuss your legal issue.


Source: Press Release

Contact Information